MIRLET7A2: A Potential Drug Target and Biomarker (G406882)

Target Name: MIRLET7A2

NCBI ID: G406882

MIRLET7A2

MIRLET7A2: A Potential Drug Target and Biomarker

MIRLET7A2, a gene located on chromosome 11q22, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The gene encodes a non-coding RNA molecule that has been shown to regulate the expression of several genes, including those involved in cell growth, differentiation, and survival.

While the exact mechanism of how MIRLET7A2 regulates these genes remains unclear, it is known that it plays a crucial role in the regulation of stem cell properties and proliferation. MIRLET7A2 has been shown to promote the self-renewal and survival of stem cells, and it has been linked to the development and maintenance of various stem cell populations, including neural stem cells, hematopoietic stem cells, and embryonic stem cells.

MIRLET7A2 has also been shown to play a role in the regulation of cell death, with studies indicating that it can either promote or inhibit cell apoptosis depending on the context. In addition, MIRLET7A2 has been linked to the regulation of inflammation and immune cell function, which could make it a potential target for the development of drugs for autoimmune disorders.

The potential drug target status of MIRLET7A2 is supported by several findings. First, there is a strong body of evidence suggesting that MIRLET7A2 has been implicated in the development of various diseases, including cancer. For example, studies have shown that MIRLET7A2 is frequently deleted or mutated in various types of cancer, and that these genetic changes can lead to the development of cancer. Additionally, MIRLET7A2 has been shown to be involved in the regulation of cell cycle progression, which is a critical step in the development of cancer cells.

Another finding that supports the potential drug target status of MIRLET7A2 is its involvement in neurodegenerative diseases. MIRLET7A2 has been shown to be involved in the regulation of the production of glial cells, which are a type of nerve cell that support the function of nerve fibers. The loss of glial cells has been linked to a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Finally, MIRLET7A2 has also been shown to be involved in the regulation of autoimmune disorders. MIRLET7A2 has been shown to be involved in the regulation of T cell development and function, which are critical for the development and response of the immune system. The development of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, is often associated with the dysfunction of the immune system, and MIRLET7A2 has been shown to play a role in this process.

In conclusion, the potential drug target and biomarker status of MIRLET7A2 is clear. Its involvement in the regulation of stem cell properties, cell death, inflammation, and immune cell function makes it a promising target for the development of drugs for a variety of diseases. Further research is needed to fully understand the mechanism of MIRLET7A2 and its potential as a drug target.

Protein Name: MicroRNA Let-7a-2

The "MIRLET7A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIRLET7A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets